Source - MicroSmallCap
San Francisco, California–(Newsfile Corp. – October 16, 2020) – Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims.
Relevant Period: Before July 21, 2020
Contact An Attorney Now: FIXX@hbsslaw.com
Homology Medicines, Inc. (FIXX) Investigation:
Homology Medicines is a Boston, MA-based gene therapy company focused on curing rare genetic diseases.
The investigation centers on the accuracy of Homology Medicines’ statements concerning the efficacy of its ...